Proactive Investors - Run By Investors For Investors

Genetic Technologies surges after colorectal and breast cancer genetic risk tests

The breast cancer and colorectal tests will provide healthcare providers and their patients with risk assessments of the patient developing breast cancer.
Work in laboratory
Shares surged by around 70% to 1.2 cents in intra-day trading

Genetic Technologies Limited (ASX:GTG) has completed and validated two ground-breaking cancer risk assessment tests for colorectal and breast cancer.

This breakthrough follows substantial scientific research and genetic product development with investors respondings positively.

Branded as ‘GeneType for Colorectal Cancer’ and ‘GeneType for Breast Cancer’, the tests combine information from genetic markers called Single Polymorphisms.

These markers assess how people’s genetic make-up affects their risk of developing various diseases.

The company’s heavily patented approach to incorporating clinical risk information places it at the forefront of the global risk assessment space.

Test allow government leaders to target “most high-risk patients”

Genetic Technologies chairman and acting CEO Paul Kasian said: “These tests allow government health leaders to target future screening to the most high-risk patients - massively reducing health system costs.

“GTG’s proactive approach to disease management has the potential to save both lives and money by allowing the earlier detection of disease and focusing the use of healthcare resources to those most in need.”

Genetic testing is “a growing industry”

Kasian added: “I am very proud of our world-class scientific team – genetic testing is a growing industry and it is remarkable that the team has maintained thought and product development leadership in this competitive space.”

The breast cancer test provides substantial improvement over GTG’s legacy breast cancer test (previously called BREVAGENplus) by incorporating multiple clinical risk factors.

 

The colorectal test evaluates the genometric risk of developing colorectal cancer for men and women over age 30 who do not have a known pathogenic gene variant.

GTG’s scientific and product development will refocus on its future pipeline of new tests following the completion of the colorectal and breast cancer tests.

 

View full GTG profile View Profile

Genetic Technologies Timeline

Newswire
March 06 2015

Related Articles

rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
cannabis
February 28 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use